FDA Clears AI Platform for Heart Procedure Planning
Cardiology has been recognized for its significant role in healthcare, particularly with the increasing integration of artificial intelligence (AI). Recently, the U.S. Food and Drug Administration (FDA) cleared an AI platform developed by DASI Simulations for use in planning transcatheter aortic valve replacement (TAVR) and other heart procedures. This highlights cardiology's ongoing momentum as a leader in AI technology, second only to radiology in AI algorithm approvals.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
